📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Permeability of the blood-brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis. (2018)

First Author: Cramer SP

Attributed to: Systemic inflammation and the blood-brain barrier in multiple sclerosis funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/ana.25219

PubMed Identifier: 29604233

Publication URI: http://europepmc.org/abstract/MED/29604233

Type: Journal Article/Review

Volume: 83

Parent Publication: Annals of neurology

Issue: 5

ISSN: 0364-5134